Author:
Xiao Xiang,Zhang Cheng,Ma Xiaotang,Miao Huilai,Wang Jinju,Liu Langni,Chen Shuzhen,Zeng Rong,Chen Yanfang,Bihl Ji C.
Funder
National Institutes of Health
American Heart Association
National Natural Science Foundation of China
Reference55 articles.
1. The angiotensin converting enzyme 2/Ang-(1-7) axis in the heart: a role for MAS communication?;Stewart;Circ. Res.,2008
2. The renin–angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition;Atlas;J. Manag. Care Pharm.,2007
3. The renin–angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease;Volpe;J. Am. Soc. Nephrol.,2002
4. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients;Vijan;J. Indian Med. Assoc.,2009
5. Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?;van de Wal;Eur. Heart J.,2005
Cited by
66 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献